Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in ChinaGlobeNewsWire • 06/10/22
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric CancerGlobeNewsWire • 06/03/22
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual ConferenceGlobeNewsWire • 05/31/22
Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022GlobeNewsWire • 05/20/22
Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune ThrombocytopeniaGlobeNewsWire • 05/05/22
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 StudyGlobeNewsWire • 04/28/22
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company's Independent Registered Public Accounting FirmGlobeNewsWire • 04/21/22
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLABPRNewsWire • 04/18/22
ZLAB Investor Notice: ROSEN, A Leading Law Firm, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLABNewsfile Corp • 04/07/22
ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLABPRNewsWire • 04/04/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the FirmBusiness Wire • 04/01/22
EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLABBusiness Wire • 03/31/22
Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting riskMarket Watch • 03/26/22
Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022GlobeNewsWire • 03/23/22
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology MeetingGlobeNewsWire • 03/21/22
SHAREHOLDER ALERT: Investigation of Zai Lab (ZLAB) Announced by Holzer & Holzer, LLCNewsfile Corp • 03/18/22